

94. (Amended) A fusion protein comprising a polypeptide of any one of claims 17, 18, or 80- 92.

101. (Amended) A composition comprising a polypeptide of any one of claims 17, 18, 80-93, or 97.

102. (Amended) A pharmaceutical composition comprising a polypeptide of any one of claims 17, 18, 80-93, or 97, and a carrier.

REMARKS

Status of the Claims

The currently pending claims are claims 17, 18, 80-94, 97, 101, 102, and 104. Claims 95, 96, 98-100, and 103 have been cancelled without prejudice or disclaimer of the subject matter claimed therein. Claims 17, 18, 80-93, and 97 have been indicated as allowable. Claims 94, 101, and 102 have been amended.

Amendments to the Claims

Claim 94, 101, and 102 have been amended to correct the dependencies of the claim in view of the cancellation of claims 95, 96, 98-100, and 103.

Rejection of the Claims Under 35 U.S.C. § 112, Second Paragraph

Claims 94, 103, and 104 have been rejected under 35 U.S.C. § 112, second paragraph as being indefinite. In view of the amendment to claim 94 and the cancellation of claim 103 without prejudice, Applicant respectfully submits that this rejection has become moot.

Rejection of the Claims Under 35 U.S.C. § 112, First Paragraph

Claims 95, 96, and 98-104 have been rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification. In view of the

amendments to claims 101 and 102 and the cancellation of claims 95, 96, and 98-100 without prejudice, Applicant respectfully submits that the rejection has become moot.

Conclusion

In view of the amendments and accompanying remarks, Applicant respectfully requests reconsideration and timely allowance of the pending claims. Should the Examiner feel that there are any issues outstanding after consideration of this response, the Examiner is invited to contact Applicant's undersigned representative to expedite prosecution.


If there are any other fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully Submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: March 10, 2003

By:


Sally P. Teng
Reg. No. 45,397

Customer No. 09629


MORGAN, LEWIS & BOCKIUS LLP

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel.: (202)-739-3000

Fax: (202)-739-3001



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claim 94 has been amended as follows:

94. (Amended) A fusion protein comprising a polypeptide of any one of claims 17, 18, or 80-~~[93]~~ 92.

Claim 101 has been amended as follows:

101. (Amended) A composition comprising a polypeptide of any one of claims 17, 18, 80-93, or ~~[95-99]~~ 97.

Claim 102 has been amended as follows:

102. (Amended) A pharmaceutical composition comprising a polypeptide of any one of claims 17, 18, 80-93, or ~~[95-99]~~ 97, and a carrier.